Target intelligence / Profile preview

Nuclear factor of activated T-cells, cytoplasmic 3 (NFATc3)

Target
NFATc3
Molecular classification
Transcription factor, DNA-binding protein, Calcium-dependent transcription factor
01

Overview

Nuclear factor of activated T-cells, cytoplasmic 3 (NFATc3) is a member of the NFAT family of transcription factors, encoded by the NFATC3 gene in humans. It is chiefly expressed in the thymus and immune cells (particularly T cells and macrophages), where it regulates inducible gene expression, most notably cytokines such as IL-2 and TNFα. NFATc3 is maintained as a phosphorylated cytoplasmic protein in resting cells; upon stimulation (typically via antigen receptor signaling), a calcium/calcineurin pathway triggers its dephosphorylation and nuclear import, enabling binding to DNA and transcriptional activation of immune/inflammatory genes. NFATc3 also influences differentiation and gene expression in non-lymphoid cell types (such as adipocytes and macrophages). Dysregulation of NFATc3 is implicated in cancer progression (as seen in PDAC), immune disorders, and inflammatory lung injury, making it a therapeutic target for immunosuppressive drugs and biomarker studies.

Other names
NFATc3NFAT4NF-AT4NF-ATc3NFATXT-cell transcription factor NFAT4Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3
02

Mechanism of action

Inhibition of calcineurin phosphatase blocks dephosphorylation and nuclear import of NFAT family members, including NFATc3, thereby suppressing cytokine gene transcription and immune activation.

03

Biological functions

Regulation of gene expression in T cells and thymocytesInducible expression of cytokine genes (e.g., IL-2, TNFα, CCR2)Immune responseInflammationCell signaling in differentiation (adipocyte, macrophage)
04

Disease associations

Cancer (notably pancreatic ductal adenocarcinoma (PDAC))Inflammation (regulation of macrophage function in sepsis-induced acute lung injury)Immune disordersPotential role in metabolic disease (adipocyte differentiation)
05

Safety considerations

Immunosuppression (risk of infection, malignancy) due to systemic inhibition (ex: calcineurin inhibitors)Off-target effects on non-immune cell types where NFATc3 is active (e.g., metabolic tissues)
06

Interacting drugs

Cyclosporin A (CsA)

1 more in the full profile.

07

Biomarkers

Nuclear localization/expression levels of NFATc3 in tumor tissues serves as a biomarker for aggressiveness and poor prognosis in pancreatic ductal adenocarcinomaNFAT-dependent cytokine gene expression (e.g., IL-2, TNFα, CCR2)

Beyond the preview

Go deeper on Nuclear factor of activated T-cells, cytoplasmic 3 (NFATc3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear factor of activated T-cells, cytoplasmic 3 (NFATc3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call